

Consolidated Financial Results for the Third Quarter of Fiscal Year 03/2013

Consolidated Subsidiaries: 3

Kissei Shoji Co., Ltd. / Kissei Comtec Co., Ltd. / Hashiba Technos Co., Ltd.

Consolidated	Third Quarter of Fiscal Y03/2012 Apr. 2011 - Dec. 2011		Third Quarter of Fiscal Y03/2013 Apr. 2012 - Dec. 2012			YoY
	Mil. of US\$	Ratio	Mil. of US\$	Mil. of Yen	Ratio	
Net Sales	560.8	100.0%	537.1	46,509	100.0%	4.2%
Cost of Sales	193.1	34.4%	172.4	14,927	32.1%	10.7%
Gross Profit	367.7	65.6%	364.7	31,581	67.9%	0.8%
Selling, General and Administrative Expenses	293.2	52.3%	282.3	24,448	52.6%	3.7%
Operating Income	74.5	13.3%	82.4	7,133	15.3%	10.5%
Net Income	45.7	8.1%	50.5	4,369	9.4%	10.4%

Note: US dollar amounts are translated at the rate of ¥86.6 = US\$1.

Financial Forecasts for Annual 03/2013

Consolidated	Results of Annual 03/2012 Apr. 2011 - Mar. 2012			Forecasts for Annual 03/2013 Apr. 2012 - Mar. 2013			YoY
	Mil. of US\$	Mil. of Yen	Ratio	Mil. of US\$	Mil. of Yen	Ratio	
Net Sales	746.2	64,618	100.0%	721.7	62,500	100.0%	3.3%
Cost of Sales	263.8	22,848	35.4%	249.4	21,600	34.6%	5.5%
Gross Profit	482.3	41,770	64.6%	472.3	40,900	65.4%	2.1%
Selling, General and Administrative Expenses	396.1	34,305	53.1%	392.6	34,000	54.4%	0.9%
Operating Income	86.2	7,465	11.6%	79.7	6,900	11.0%	7.6%
Net Income	55.1	4,769	7.4%	48.5	4,200	6.7%	11.9%

¥86.6 = US\$1

Trends in Business Performance

(Millions of Yen except Number of Employees)

Consolidated	03/2009	03/2010	03/2011	03/2012	03/2013 Forecasts
Net Sales	64,535	62,178	64,393	64,618	62,500
Operating Income	6,393	6,584	6,463	7,465	6,900
(% of Net Sales)	(9.9)	(10.6)	(10.0)	(11.6)	(11.0)
Extraordinary Gain or Loss	2,815	604	604	251	850
Net Income	2,061	4,371	4,004	4,769	4,200
(% of Net Sales)	(3.2)	(7.0)	(6.2)	(7.4)	(6.7)
R&D Expenses	11,556	10,786	12,037	10,043	10,700
(% of Net Sales)	(17.9)	(17.3)	(18.7)	(15.5)	(17.1)
Depreciation and Amortization	3,709	3,233	2,809	2,633	2,390
Capital Investment	1,414	2,037	1,322	1,893	1,720
Export Value	2,917	1,746	2,647	2,793	3,930
Number of Employees	1,870	1,920	1,911	1,893	-

< Years ended / ending March 31 >

Trends in Main Product Sales

(Millions of Yen)

Products	03/2011 Results	03/2012 Results	03/2012 3Q Results	03/2013 3Q Results	03/2013 Forecasts
URIEF	9,723	11,156	8,551	8,939	11,850
GLUFAS	5,160	4,299	3,431	2,746	3,490
GLUBES	—	668	442	1,265	1,820
SALAGEN	990	1,046	807	894	1,160
EPOETIN ALFA BS INJECTION	1,251	2,899	2,159	3,393	4,480
BEZATOL	7,459	7,091	5,581	4,694	6,120
UTEMERIN	4,627	4,338	3,389	3,174	4,010
XANBON	1,697	1,467	1,189	984	1,250
RIZABEN Eye Drops	2,665	2,086	1,186	1,078	1,760
RIZABEN	1,911	1,723	1,311	1,213	1,600
DOMENAN	312	257	203	177	230
FRAGMIN	837	595	475	375	460
RYSMON TG	874	648	514	440	550
ZOLADEX 1.8mg Depot	805	693	523	532	670
FULSTAN	647	622	494	510	640

< Years ended / ending March 31 >